TLS Advisors LLC Sells 90,564 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID)

TLS Advisors LLC cut its position in Ovid Therapeutics Inc. (NASDAQ:OVID) by 11.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 680,967 shares of the company’s stock after selling 90,564 shares during the quarter. Ovid Therapeutics comprises about 1.5% of TLS Advisors LLC’s holdings, making the stock its 11th largest position. TLS Advisors LLC owned about 0.96% of Ovid Therapeutics worth $636,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in OVID. Takeda Pharmaceutical Co. Ltd. purchased a new position in Ovid Therapeutics in the 4th quarter valued at approximately $7,012,000. Geode Capital Management LLC boosted its holdings in shares of Ovid Therapeutics by 1.1% in the third quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock worth $1,555,000 after acquiring an additional 14,816 shares during the period. BNP Paribas Financial Markets grew its position in shares of Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after purchasing an additional 215,189 shares in the last quarter. Monimus Capital Management LP bought a new stake in shares of Ovid Therapeutics during the 4th quarter valued at $129,000. Finally, Barclays PLC increased its position in shares of Ovid Therapeutics by 311.2% during the third quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after buying an additional 63,702 shares during the period. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on OVID. Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective for the company in a research note on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Ovid Therapeutics in a report on Wednesday, December 4th. BTIG Research lowered their target price on shares of Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday, March 24th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $3.00 price objective (down previously from $4.00) on shares of Ovid Therapeutics in a research note on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Ovid Therapeutics presently has an average rating of “Buy” and an average target price of $3.03.

Ovid Therapeutics Price Performance

OVID stock opened at $0.35 on Friday. The stock has a market capitalization of $24.88 million, a price-to-earnings ratio of -0.74 and a beta of 0.29. The firm’s 50-day moving average price is $0.57 and its two-hundred day moving average price is $0.91. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. Ovid Therapeutics Inc. has a 12-month low of $0.35 and a 12-month high of $3.45.

Ovid Therapeutics (NASDAQ:OVID) last posted its earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.19 million. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. As a group, equities analysts predict that Ovid Therapeutics Inc. will post -0.4 earnings per share for the current year.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.